Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 831-838

  Zhang, Chengyao ^a   Wang, Jiawu ^b   Gu, Haitao ^a   Zhu, Daihua ^a   Li, Yang ^a   Zhu, Peng ^a   Wang, Yaxu ^a   Wang, Jijian ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Steel Group General Hospital of Chongqing   (China)

Author keywords

Capecitabine; Meta analysis; Metastatic colorectal cancer; Oxaliplatin

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEVER; HAND FOOT SYNDROME; HUMAN; META ANALYSIS; METASTASIS; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84863138482     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.567     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics. CA Cancer J Clin 57: 43-66, 2009.
2. Goldberg RM, Rothenberg ML, Van Cutsem E, et al: The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 12: 38-50, 2007.
3. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. Clin Oncol 19: 2282-2292, 2001.
4. Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 17: 1-12, 1996.
5. Rothenberg ML, Cox JV, Butts C, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19: 1720-1726, 2008.
6. Porschen R, Arkenau HT, Kubicka S, et al: Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: a randomized comparison in metastatic colorectal cancer-a final report of the AIO Colorectal Study Group. J Clin Oncol 25: 4217-4223, 2007.
7. Ducreux M, Bennouna J, Hebbar M, et al: Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. Int J Cancer 128: 682-690, 2011.
8. Van Cutsem E, Rivera F and Berry S: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20: 1842-1847, 2009.
9. Diaz-Rubio E, Tabernero J, Gomez-Espana A, et al: Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 25: 4224-4230, 2007.
10. Comella P, Massidda B, Filippelli G, et al: Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/ leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. J Cancer Res Clin Oncol 135: 217-226, 2009.
11. Cassidy J, Clarke S, Diaz-Rubio E, et al: A randomized phase III study of capecitabine plus oxaliplatin (XELOX) versus fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26: 2006-2012, 2008.
12. de Gramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
13. Kouroussis C, Souglakos J, Kakolyris S, et al: Oxaliplatin in combination with infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: a phase II study. Oncology 61: 36-41, 2001.
14. Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34: 1274-1281, 1998.
15. Cassidy J and Tabernero J: XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 22: 2084-2091, 2004.
16. Borner MM, Dietrich D, Stupp R, et al: Phase II study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in first and second line treatment of advanced or metastic colorectal cancer. J Clin Oncol 20: 1759-1766, 2002.
17. Zeuli M, Nardoni C, Pino MS, et al: Phase II study of capecitabine and oxaliplatin as first-line treatment in advanced colorectal cancer. Ann Oncol 14: 1378-1382, 2003.
18. Shields AF, Zaupski MM, Marshall JL, et al: Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer 100: 531-537, 2004.
19. Comella P, Natale D, Farris A, et al: Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma final results of the southern Italy Cooperative Oncology Group Trial 0108. Cancer 104: 282-289, 2005.
20. Feliu J, Salud A, Escudero P, et al: XELOX (Capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94: 969-975, 2006.
21. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 19: 4097-4106, 2001.
22. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/ leucovorin. Ann Oncol 13: 566-575, 2002.